• Korean Journal of Pharmacognosy
• /
• v.32 no.2 s.125
• /
• pp.108-115
• /
• 2001

Based on DPPH radical scavenging activity and lipid peroxidation inhibitory activity, the MeOH extracts of 139 crude drugs were screened in order to search for antioxidants. Among tested samples, the extracts from the seed of Nelumbo nucifera, the fruit of Terminalia chebula var. gangetia, the root of Salvia miltiorhiza, the fruit of Ziziphus jujuba var. innermis, the root bark of Paeonia moutan, the fruit of Rubus coreanus, the fruit of Zanthoxylum schinifolium, the lignum of Caesalpinia sappan, the leaf of Pinus densiflora, the rhizome of Alpinia officinarum, the fruit of Syzygium aromaticum, the ramulus and uncus of Uncaria rhynchophylla, the root bark of Lycium chinense, and the fruit of Alpinia katsumadai showed a relatively strong antioxidative activity. Furthermore, the BuOH fraction from the extract of N. nucifera showed a potent activity in each assay. The isolation of bioactive compounds has been carried out and will be reported in the next paper.

• The Journal of Pediatrics of Korean Medicine
• /
• v.36 no.1
• /
• pp.38-56
• /
• 2022

Objectives The purpose of this study was to analyze the trend of recent randomized controlled trials (RCTs) that used herbal medicine for the treatment of tic disorders in China and to evaluate the efficacy and safety of the treatment. Methods RCTs published from January 2017 to December 2021 were searched for using the China National Knowledge Infrastructure (CNKI). These were then analyzed using herbal medicine treatment methods and their results. Results A total of 35 randomized controlled trials were selected and analyzed. In most studies, evaluation indicators such as the Yale tic symptom scale and total effective rate were significantly improved in the herbal medicine treatment group compared to the control group. The most commonly used herb for tic disorder was Uncaria Rhynchophylla (釣鉤藤), followed by Glycyrrhizae Radix (甘草), Gastrodiae Rhizoma (天麻), Paeoniae Radix Alba (白芍藥), Batryticatus (白殭蠶), Poria (茯笭), and Bupleuri Radix (柴胡). In all studies that reported adverse events, herbal medicine was identified as a relatively safe treatment with fewer adverse reactions or no significant difference compared with the control group. Conclusions Based on the results of RCTs, herbal medicine has been shown to be safe and effective for the treatment of intellectual disability. However, additional well-designed large-scale clinical trials are needed to confirm these findings.

• Biomolecules & Therapeutics
• /
• v.30 no.6
• /
• pp.553-561
• /
• 2022

Chronic myeloid leukemia (CML) is a slowly progressing hematopoietic cell disorder. Sphingosine kinase 1 (SPHK1) plays established roles in tumor initiation, progression, and chemotherapy resistance in a wide range of cancers, including leukemia. However, small-molecule inhibitors targeting SPHK1 in CML still need to be developed. This study revealed the role of SPHK1 in CML and investigated the potential anti-leukemic activity of hirsuteine (HST), an indole alkaloid obtained from the oriental plant Uncaria rhynchophylla, in CML cells. These results suggest that SPHK1 is highly expressed in CML cells and that overexpression of SPHK1 represents poor clinical outcomes in CML patients. HST exposure led to G2/M phase arrest, cellular apoptosis, and downregulation of Cyclin B1 and CDC2 and cleavage of Caspase 3 and PARP in CML cells. HST shifted sphingolipid rheostat from sphingosine 1-phosphate (S1P) towards the ceramide coupled with a marked inhibition of SPHK1. Mechanistically, HST significantly blocked SPHK1/S1P/S1PR1 and BCR-ABL/PI3K/Akt pathways. In addition, HST can be docked with residues of SPHK1 and shifts the SPHK1 melting curve, indicating the potential protein-ligand interactions between SPHK1 and HST in both CML cells. SPHK1 overexpression impaired apoptosis and proliferation of CML cells induced by HST alone. These results suggest that HST, which may serve as a novel and specific SPHK1 inhibitor, exerts anti-leukemic activity by inhibiting the SPHK1/S1P/S1PR1 and BCR-ABL/PI3K/Akt pathways in CML cells, thus conferring HST as a promising anti-leukemic drug for CML therapy in the future.